Minerva Neurosciences (NASDAQ:NERV) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a sell rating in a research note issued to investors on Sunday.

A number of other research firms have also issued reports on NERV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. HC Wainwright reduced their price objective on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $4.00.

Minerva Neurosciences Price Performance

Minerva Neurosciences stock opened at $4.45 on Friday. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $12.46. The firm has a fifty day moving average price of $3.98 and a two-hundred day moving average price of $2.93. The firm has a market cap of $192.55 million, a price-to-earnings ratio of -2.41 and a beta of -0.28.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). As a group, sell-side analysts expect that Minerva Neurosciences will post -0.3 earnings per share for the current year.

Institutional Trading of Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Apella Capital LLC boosted its holdings in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 87.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,314 shares of the biopharmaceutical company’s stock after purchasing an additional 18,375 shares during the period. Apella Capital LLC’s holdings in Minerva Neurosciences were worth $83,000 as of its most recent SEC filing. 34.56% of the stock is currently owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.